This issue affects the Dexcom G6, G7, ONE, and ONE+ receivers, with the FDA classifying it as the most serious type of recall. The malfunction has resulted in at least 56 reported injuries, although no fatalities have been reported. Meanwhile, Truist Securities has initiated coverage on Dexcom with a Buy rating, citing the company's potential in the continuous glucose monitoring market. Piper Sandler also maintained its Overweight rating on Dexcom, highlighting the company's expected market share gains among basal insulin patients. Goldman Sachs has started covering Dexcom with a Buy rating and a $104 price target, noting the untapped potential in consumer adoption. RBC Capital Markets reiterated an Outperform rating and a $100 price target, emphasizing Dexcom's potential to exceed its financial targets by 2025. These developments reflect a mix of challenges and opportunities for Dexcom, as it navigates product recalls and anticipates growth in the diabetes monitoring market.